Gilead and arcus announce new data showing encouraging clinical activity of anti-tigit domvanalimab-containing regimen as first-line treatment for upper gi cancers

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (orr) and six-month progression-free survival (pfs) rate results in a preliminary analysis from arm a1 of the edge-gastric study. this ongoing phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the fc-silent.
RCUS Ratings Summary
RCUS Quant Ranking